Azcuris Co., Ltd.

Azcuris Co. , Ltd. is a South Korea-based company focused on developing innovative small-molecule therapeutics that modulate cytokine signaling pathways to prevent and treat immune diseases. Founded in 2018 and headquartered in Sejong-si, South Korea, Azcuris Co.

, Ltd. specializes in drug discovery for immune-related conditions. The company has completed 2 deals to date, with its most recent funding round, Series A, taking place on July 31, 2020, raising KRW 4 billion. Azcuris Co.

, Ltd. specializes in the development of innovative small-molecule therapeutics aimed at modulating cytokine signaling pathways to prevent and treat immune diseases. Their primary offering revolves around a proprietary drug discovery platform that focuses on small-molecule immune therapeutics. This platform is designed to control the early stages of immune responses, effectively blocking disease progression.

Azcuris targets various immune-related conditions and aims to provide solutions for patients suffering from chronic inflammatory diseases and autoimmune disorders. The company serves a diverse client base, including research institutions, pharmaceutical companies, and healthcare providers, primarily within the Asian and European markets where immunotherapy is gaining traction. Azcuris generates revenue through strategic partnerships and collaborations with pharmaceutical companies and research organizations, focusing on the commercialization of their drug discovery platform. Typically, transactions involve licensing agreements where clients pay for access to Azcuris's proprietary technologies or collaborative agreements that may include milestone payments based on research outcomes.

The company may also engage in joint ventures with larger firms to facilitate the development and distribution of their therapeutic products. While specific pricing plans for their services are not disclosed, revenue is driven by these collaborations, which align with their mission to innovate in the field of immunotherapy. The flagship offerings, centered around cytokine modulation, position Azcuris to capitalize on the growing demand for specialized immune therapeutics in the market. In July 2020, Azcuris Co.

, Ltd. raised KRW 4 billion in Series A funding, which will be utilized to support the development of new therapeutics targeting immune diseases. The company plans to expand its reach into European markets by the end of 2023, capitalizing on the increasing demand for advanced immunotherapies. This funding is aimed at enhancing their proprietary drug discovery platform and facilitating entry into these new markets.